[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Wisconsin, Madison\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":541},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,167,0,25,[9,46,71,93,115,135,153,178,201,223,241,272,289,309,331,353,372,395,407,423,440,459,480,501,520],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053730",false,"NCT07674784","Interventions to Enhance Quadriceps Output After ACLR","Clinical Interventions to Acutely Enhance Quadriceps Output After Anterior Cruciate Ligament Reconstruction","Inclusion Criteria:\n\n* Have undergone ACLR within the previous 4 months\n* Are at least 2 months post-ACLR\n\nExclusion Criteria:\n\n* A history of ACLR on both legs\n* Since the most recent ACLR:\n\n  * secondary lower extremity surgery\n  * leg or foot fracture\n* Unable to walk without an assistive device\n* Pain of greater than 5\u002F10 during quadriceps strengthening exercises with the surgical limb\n* Cannot achieve 90 degrees of knee flexion with the surgical limb\n* People with contraindications to NMES\n* Anyone who had a previous skin reaction to NMES or attempted but could not tolerate NMES\n* Peripheral neuropathy or other neurological conditions","ALL","18 Years","40 Years",{"count":20,"type":21},22,"ESTIMATED","INTERVENTIONAL",[24],"NA","The investigators are interested in determining what treatments are effective in reducing inhibition after anterior cruciate ligament (ACL) surgery and helping people increase quadriceps strength. Two interventions that are often used clinically are neuromuscular electrical stimulation (NMES) and vibration. This is a study of how effective these treatments are, whether they work the same for everyone, and if one is better than the other. 22 participants will be enrolled and on study for 2 to 3 weeks.",[27],"ACL",[29,30,31,32],"ACLR","quadriceps","neuromuscular electrical stimulation","vibration","NOT_YET_RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":21},"2026-08",{"date":41,"type":21},"2027-08",{"name":43,"class":44},"University of Wisconsin, Madison","OTHER",1,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100625191","NCT07419425","My Path to Quit Tobacco","Comparing Three Multicomponent Interventions to Help Adults Quit Smoking","Inclusion Criteria:\n\n* self-identify as Black\n* smoke cigarettes (greater than or equal to 1 cigarette on greater than or equal to 4 days\u002Fweek)\n* motivated to quit smoking\n* willing to discontinue any non-study smoking cessation pharmacotherapy use during study treatment.\n\nExclusion Criteria:\n\n* currently taking bupropion for non-smoking cessation reasons",true,"21 Years",{"count":55,"type":21},1550,[57],"PHASE4","The overarching goal of this program of research is to reduce smoking-related health disparities by increasing smoking cessation among Black adults. The goal of this research proposal is to determine whether more intensive, culturally specific, evidence-based interventions are more effective at promoting long-term cessation and other key patient-centered outcomes compared to the usual evidence-based standard of care: services provided by a state-run quitline. This study compares the relative effectiveness of three different treatments (Standard, Intensive, and Intensive Incentivized) on long-term smoking cessation (biochemically confirmed abstinence from combusted tobacco at 26-weeks post-target quit day) among Black adults who smoke and want to quit.",[60],"Smoking Cessation","RECRUITING","2026-06-30",{"date":64,"type":37},"2026-07-01",{"date":66,"type":21},"2026-07",{"date":68,"type":21},"2030-01",{"name":43,"class":44},5,{"id":72,"slug":4,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":45},"100629470","NCT07475091","Standardizing Swallow Pressure Measurements","Pharyngeal High Resolution Manometry Standardization of Metrics","Inclusion Criteria:\n\n* without known swallowing disorders\n\nExclusion Criteria:\n\n* Known swallowing disorder\n* Allergy to topical anesthetic\n* Allergy to food relevant to study participation (e.g. lactose intolerance)\n* Inability to follow direction or remain calm during the experiment.","99 Years",{"count":7,"type":21},[24],"This study aims to directly compare and contrast swallowing pressure and impedance measurements obtained from two high-resolution manometry (HRM) systems: the Laborie LMT Pharyngeal System and the Medtronic ManoScan ESO HRM System in healthy adult volunteers. The primary objective is to determine how differences in catheter diameter, sensor configuration, and acquisition platforms influence measurement outcomes. Twenty-five healthy adults will participate in a single, approximately 2-hour visit; the study will be open for one year for data collection and two years for data analysis.",[82],"Dysphagia",[84,85,86,87],"pharyngeal pressure events","swallowing","measurement","diagnosis",{"date":64,"type":37},{"date":66,"type":21},{"date":91,"type":21},"2027-06",{"name":43,"class":44},{"id":94,"slug":4,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":52,"sex":16,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":45},"100624754","NCT07413744","The Gut - PRO Study","Probiotic Supplementation Safety and Feasibility Study in Preclinical Alzheimer's Disease","Inclusion Criteria:\n\n* MCI\u002FAD or cognitively unimpaired, referred from a Wisconsin clinic that is part of the Wisconsin Alzheimer's Institute's (WAI) network, or recruited from the community. May have participated in:\n\n  * Alzheimer's Disease Research Center (ADRC) clinical core study (2011-0030)\n  * ADCP (26695, MCW IRB)\n  * Synapse study (2018-1283)\n  * ADRC Recruitment Registry (2016-0735)\n* At least 60 years of age or older\n* Good general health (other than cognitive impairment\u002Fdementia) with no conditions\u002Fmedications affecting the gut microbiome (see exclusion criteria below)\n* Willing and able to comply with all study procedures for the duration of the study\n* Able to provide signed and dated informed consent form\n* Participant is not pregnant, lactating or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile)\n* Able to take oral medications\n* An informant to answer questionnaires about the participant\n\nAdditional inclusion criteria for unimpaired participants:\n\n* Has MOCA score that falls within the range defined for cognitively healthy individuals\n\nAdditional inclusion criteria for participants with MCI\u002FAD\n\n* Abnormal cognitive function documented by neuropsychological testing\n* ADRC (2015-0030) Consensus Diagnosis Conference indicates dementia or MCI due to AD (for ADRC, ADCP, and Synapse participants only)\n* Meets NIA-AA criteria for MCI or AD.\n\nExclusion Criteria:\n\n* Active or previous (within 6 months) participation in an Alzheimer's clinical intervention\u002Ftrial (can be included if previously enrolled in placebo or control group)\n* Standard clinical care for dementia and medications used to treat MCI and Alzheimer's disease are acceptable, including monoclonal antibody therapy\n* Significant neurologic disease: Any significant neurologic disease, such as Parkinson's disease, stroke, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, subdural hematoma, multiple sclerosis, seizure disorder, or other significant deficits other than Alzheimer's or Mild Cognitive Impairment\n* Alcohol\u002Fsubstance: history of alcohol\u002Fsubstance dependence in the past year.\n* Significant medical illness: any significant systemic illness or unstable medical condition occurring during ADRC participation that could affect cognition (other than MCI\u002FAD). Examples include malignant cancer, chemotherapy, HIV, untreated thyroid disease, heart failure, or renal insufficiency\n* Current diagnosis with diabetes\n* Illiterate, blind, or non-English speaking\n* Known periodic antibiotic use (i.e., prior to dental appointments)\n* Oral PS-specific exclusion criteria:\n\n  * Inability (e.g., dysphagia) or unwilling to swallow capsules\n  * Active gastrointestinal infection at time of enrollment\n  * Known or suspected toxic megacolon and\u002For known small bowel ileus\n  * History of total colectomy or bariatric surgery\n  * Concurrent intensive induction chemotherapy, radiation therapy, or biological treatment for active malignancy\n  * Unable or unwilling to comply with protocol requirements\n  * Expected life expectancy less than 6 months\n  * Previous use of probiotic supplementation (PS) or microbiome-based products within 2 months, large doses of commercial probiotics consumed (greater than or equal to 10\\^8 cfu or organisms per day). Includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component (ordinary dietary components such as fermented beverages\u002Fmilks, yogurts, foods do not apply). Enrollment after 2 months without probiotic use can be considered for eligibility\n  * Patients with severe anaphylactic or anaphylactoid food allergy\n  * Solid organ transplant recipients less than or equal to 90 days post-transplant or on active treatment for rejection\n  * A condition that would jeopardize the safety or rights of the participant, would make it unlikely for the participant to complete the study, or would confound the results of the study\n* Exclusionary factors affecting the microbiome:\n\n  * Previous use of systemic antibiotics (intravenous, intramuscular, or oral) within 3 months (depends on the duration of antibiotic use, i.e., less than 3 months is considered exclusion, however, enrollment after 3 months without antibiotic use can be considered for eligibility)\n  * Immune stimulating and\u002For suppressing medications\n  * Immunosuppressed as evaluated by complete blood count (CBC) with differential, which includes white blood cell count, total neutrophil count, and total lymphocyte count\n  * Unstable dietary history during the previous month, which is defined as major changes in diet by eliminating or significantly increasing a major food group\n  * Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years\n  * Major bowel resection at any time\n  * Active uncontrolled gastrointestinal disorders or disease including inflammatory bowel disease, ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis; irritable bowel syndrome (moderate-severe); persistent, infectious gastroenteritis, colitis, or gastritis; persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated), or chronic constipation","60 Years",{"count":101,"type":21},40,[103],"PHASE2","The purpose of this study is to assess the safety and feasibility of an oral probiotic supplement (PS) intervention in individuals with dementia or mild-cognitive impairment (MCI) due to Alzheimer's disease or at risk of dementia due to Alzheimer's disease (AD). 40 participants will be enrolled and can expect to be on study for up to 1 year.",[106],"Alzheimer Disease",[108],"probiotics",{"date":110,"type":37},"2026-07-02",{"date":39,"type":21},{"date":113,"type":21},"2029-03",{"name":43,"class":44},{"id":116,"slug":4,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":45},"100620644","NCT07360301","Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study","Inclusion Criteria:\n\n* Age 18 to 45 years (inclusive) at screening, of any identified gender and racial\u002Fethnic group\n* Physically healthy; does not meet criteria for an exclusionary medical condition\n* No exclusionary sleep condition\n* English-speaking (able to provide consent and complete questionnaires)\n* Sub-optimal self-reported wellbeing\n\nExclusion Criteria:\n\n* Exclusionary DSM-5 psychiatric diagnosis and\u002For active suicidal ideation\n* Exclusionary medical conditions or sleep conditions\n* Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)\n* Clinically significant electrocardiogram (ECG)\n* Use of psychotropic or CNS-altering medications within 3 months of screening\n* Hypertension or tachycardia","45 Years",{"count":122,"type":21},120,[124],"PHASE1","This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the \"trip\") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months.",[127,128],"Well-Being, Psychological","Psychedelic Experiences",{"date":110,"type":37},{"date":131,"type":21},"2026-09",{"date":133,"type":21},"2028-02",{"name":43,"class":44},{"id":136,"slug":4,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":45},"100605855","NCT07167953","The Spiral MRI Study","MRI Technology for Greater Efficiency and Improved Value","Healthy Controls Inclusion Criteria:\n\n* Adults at least 18 years\n* Able to provide written informed consent on their own behalf\n\nBrain MR Inclusion Criteria:\n\n* Adults at least 18 years\n* Able to provide written informed consent on their own behalf\n* Scheduled for standard of care brain MRI\n\nExclusion Criteria (ALL):\n\n* Unable or unwilling to provide informed consent\n* Contraindication(s) to or inability to undergo MRI\n* Currently pregnant\n* Participants requiring intravenous (IV) conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI will be allowed as long as the following criteria are met:\n* participant has their own prescription for the medication\n* informed consent process is conducted prior to the self-administration of the medication\n* they come to the research visit with a driver",{"count":142,"type":21},131,[24],"The goal of this clinical trial is to find out if new Magnetic Resonance Imaging (MRI) computer software will:\n\n* help make scans and exams faster\n* reduce artifacts\n* make MRI easier to understand\n* allow technicians to focus more on the participant and less on the scanner\n\nParticipants will complete one brain MRI imaging session, lasting about 60 minutes.",[146],"Brain MRI",{"date":64,"type":37},{"date":149,"type":21},"2028-08",{"date":151,"type":21},"2031-05",{"name":43,"class":44},{"id":154,"slug":4,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":45},"100644099","NCT07664527","Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate","A Proof-of-Concept Study of a Novel Method for Removal of Residual Oropharyngeal Inhaled Corticosteroid Deposits in Asthma","EVOOW","Inclusion Criteria:\n\n* Healthy adults and adults with asthma, age 18 years and older\n* Willing to hold orally and nasally inhaled corticosteroids (ICS) for 24h and 12h, respectively, before study visits with mouthwash sample collections (Visit 2 and Visit 3)\n* No systemic or topical ocular corticosteroid use for the prior 4 weeks.\n\nExclusion Criteria:\n\n* Known hypersensitivity to fluticasone propionate\n* Allergy to olives or olive oil\n* Known allergy to oxymetazoline\n* Current smoking or vaping\n* Currently pregnant or trying to become pregnant.",{"count":161,"type":21},20,[57],"This study is to find out if an Extra Virgin Olive-Oil-based Water (EVOOW) mix, removes more Fluticasone Propionate (FP) from the mouth than Water alone. 2 strengths of the EVOOW mix will be tested, one with equal parts EVOO and Water (50\u002F50) and one with 3 parts EVOO and 1 part Water (75\u002F25). Removing more FP deposits may help decrease the risk for obstructive sleep apnea (OSA), candidiasis (thrush), and speech and swallow dysfunction. Participants will be on study for up to 3 weeks.",[165],"Asthma",[167,168,169,170,171],"Fluticasone Propionate","EVOO","upper airway","oral deposits","inhaler","2026-06-29",{"date":64,"type":37},{"date":66,"type":21},{"date":176,"type":21},"2027-04",{"name":43,"class":44},{"id":179,"slug":4,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":52,"sex":16,"minAge":183,"maxAge":17,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":200,"locationsCount":45},"100639610","NCT07620964","Testing and Evaluating an Interactive Media Use Journal for Adolescents","Inclusion Criteria:\n\n* English speaking\n* has internet access\n* in the United States\n\nExclusion Criteria:\n\n* youth under the age of 13 years\n* over the age of 18 years","13 Years",{"count":185,"type":21},50,[24],"The goal of this study is to test the feasibility and acceptability of an Interactive Media Use Journal (IMUJ) co-developed with youth.\n\nThis study is part of a larger effort using Intervention Mapping to co-develop this resource, test it for feasibility and acceptability via this proposed protocol, and then eventually disseminate the resource in partnership with the American Academy of Pediatrics.\n\n50 participants between the ages of 13-18 will be recruited for this study",[189,190],"Social Media","Adolescent Behavior",[192,193,194,195,196],"social media engagement","health","behavior change","habit","intervention mapping",{"date":64,"type":37},{"date":66,"type":21},{"date":39,"type":21},{"name":43,"class":44},{"id":202,"slug":4,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":220,"leadSponsor":222,"locationsCount":45},"100632997","NCT07520955","Lily's Grace Temporal Interference","Using Temporal Interference to Non-Invasively Enhance Sleep Homeostasis in Patients With Epilepsy","SLEEP-TIES","Inclusion Criteria:\n\n* English-speaking (able to provide consent and complete questionnaires)\n* Citizen or holding permanent resident status\n* History of refractory epilepsy with intractable seizures and\u002For cognitive decline\n\nExclusion Criteria:\n\n* Any current or past history of neurological disorders or acquired neurological disease other than epilepsy (e.g. stroke, traumatic brain injury), including intracranial lesions\n* Current history of poorly controlled headaches including intractable or poorly controlled migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* Possible pregnancy or plan to become pregnant in the next 6 months\n* Any metal in the head\n* Any metal in the body\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator) unless otherwise approved by the responsible MD\n* Dental implants\n* Permanent retainers\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for several hours\n* Regular night-shift work (second or third shift)","75 Years",{"count":210,"type":21},24,[24],"This study is to evaluate the effectiveness of targeted Transcranial Electrical Stimulation with Temporal Interference (TES-TI) interventions to boost Non-Rapid Eye Movement (NREM) sleep, decrease seizures and promote emotional health in patients with epilepsy. Up to 24 participants (8 control participants for technical optimization prior to recruitment and 16 patients with epilepsy) will be enrolled and can expect to be on study for up to 24 months.",[214],"Epilepsy",[216,217],"seizures","non rapid eye movement sleep",{"date":64,"type":37},{"date":66,"type":21},{"date":221,"type":21},"2028-04",{"name":43,"class":44},{"id":224,"slug":4,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":240,"locationsCount":45},"100629257","NCT07472322","ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1","UW26001 Phase I\u002FII Study on the Safety, Tolerability, and Preliminary Efficacy of ASTX727 (Decitabine\u002FCedazuridine) and Retifanlimab-dlwr in Patients With Advanced Merkel Cell Carcinoma Who Have Progressed on Anti-PD-(L)1 Inhibitor","Inclusion Criteria:\n\n* Individuals age ≥ 18 years at the time of consent\n* ECOG Performance Status of 0-2\n* Histological or cytological evidence\u002Fconfirmation of Merkel cell carcinoma (MCC)\n* Must have unresectable stage III\u002FIV MCC per American Joint Committee on Cancer (AJCC) 8th edition. Participants must be considered unresectable based on the judgment of the treating physician\n* Participants must have progressed on prior programmed cell death protein-1 (PD-1) or programmed death-ligand 1(PD-L1) inhibitor-based therapy. Participants must have received at least 2 doses of anti-PD-1 or anti-PD-L1 inhibitor. Relapsed\u002Frefractory disease from prior adjuvant PD-1 or PD-L1 inhibitor is permitted. Prior treatment with retifanlimab is permitted.\n* Demonstrate adequate organ and marrow function; all screening labs to be obtained within 28 days prior to registration\n\nExclusion Criteria:\n\n* Prior treatment with a hypomethylating agent (HMA) (e.g., azacitidine, decitabine, guadecitabine)\n* History of clinically significant intolerance, hypersensitivity, or treatment discontinuation of an anti-PD-1 or anti-PD-L1 inhibitor due to grade 3 or greater immune-related adverse events (irAEs). Participants who are able to be successfully rechallenged with anti-PD-(L)1 inhibitor without recurrence of grade 3 or greater irAEs are permitted on study. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study drug(s) may be included (e.g. hearing loss, hypothyroidism, adrenal insufficiency, type 1 diabetes, or other endocrinopathies) after consultation with the sponsor investigator\n* Palliative radiation therapy administered within 1 week before the first dose of study treatment or radiation therapy in the thoracic region that is \\> 30 Gy within 6 months before the first dose of study treatment\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to registration\n* Active infection requiring systemic therapy within 7 days prior to registration",{"count":230,"type":21},31,[124,103],"The goal of this clinical trial is to learn if ASTX727 can be combined with retifanlimab to treat Merkel cell cancer. It will also learn about the safety of combining these drugs. The main questions it aims to answer are:\n\n* Can the combination shrink cancer and lower the chance of the cancer growing or spreading?\n* Is the combination better than standard of care for Merkel cell cancer?\n\nParticipants will:\n\n* Take oral ASTX727 and retifanlimab through a vein in the arm for about 2 years.\n* Visit the clinic once every 2 weeks for checkups and tests",[234,235,236],"Merkel Cell Carcinoma","Merkel Cell Carcinoma, Stage III","Merkel Cell Carcinoma, Stage IV",{"date":64,"type":37},{"date":66,"type":21},{"date":151,"type":21},{"name":43,"class":44},{"id":242,"slug":4,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":269,"leadSponsor":271,"locationsCount":45},"100614617","NCT07281924","Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","A Phase 1b\u002F2 Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of Melphalan Percutaneous Hepatic Perfusion Therapy (HEPZATO KIT™) With Nivolumab and Relatlimab (Opdualag) in Patients With Metastatic Melanoma and Liver Metastasis","Inclusion Criteria:\n\n* Histologically or cytologically confirmed metastatic melanoma with liver metastasis (LM). Liver biopsy positive for presence of melanoma metastases is required.\n* Systemic treatment naïve in the unresectable\u002Fmetastatic setting - prior adjuvant anti-programmed cell death-1 (anti-PD-1) and BRAF\u002FMEK targeted therapy is allowed but must be greater than 6 months from the last treatment.\n* Evaluable\u002Fmeasurable disease according to RECIST v1.1.\n* Demonstrate adequate organ function; all screening labs to be obtained within 28 days prior to registration.\n* Patients must weigh greater than or equal to 35 kilograms (due to possible size limitations with respect to percutaneous catheterization of the femoral artery and vein using the Delcath Hepatic Delivery System).\n\nExclusion Criteria:\n\n* Prior treatment with HEPZATO KIT™ or nivolumab and relatlimab (Opdualag™)\n* Radiotherapy is permitted within 30 days prior to C1D1 as long as radiation is given with palliative intent and towards a non-target lesion.\n* History of hypersensitivity or treatment discontinuation due to grade 3+ immune-related adverse events (irAEs) from prior anti-PD-(L)1 therapy. Patients who are able to successfully resume immune checkpoint therapy without recurrence of grade 3 irAEs are eligible to participate.\n* Symptomatic or uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation.\n* Prednisone use greater than or equal to 10 mg\u002Fd or equivalent\n* Organ transplant recipients",{"count":248,"type":21},15,[124,103],"This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in the first line setting in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.",[252,253],"Metastatic Melanoma","Liver Metastases",[255,256,257,258,259,260,261,262,263,264,265,266],"immunotherapy","Liver metastases","Anti-PD-1","Anti-LAG-3","Melphalan","Percutaneous Hepatic Perfusion Therapy","Liver directed therapy","Nivolumab","Relatlimab","Immune Checkpoint Inhibitors","Hepzato","Opdualag",{"date":64,"type":37},{"date":66,"type":21},{"date":270,"type":21},"2030-12",{"name":43,"class":44},{"id":273,"slug":4,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":52,"sex":16,"minAge":278,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":280,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":286,"leadSponsor":288,"locationsCount":45},"100605135","NCT07158580","Opti Gait Wearable Gait Tracker","Opti Gait Wearable Gait Tracker: Pilot Trial l With Healthy Older Adults","Inclusion Criteria:\n\n* Aged 65 years and older\n* Able to speak and understand English,\n* Able to provide consent\n\nExclusion Criteria:\n\n* Current or recent (\\\u003C 1 year) major psychiatric condition\n* Significant medical condition such that usability evaluation could pose substantial health or safety risk\n* Individuals with an activated power of attorney will be excluded from the study","65 Years",{"count":161,"type":21},"OBSERVATIONAL","The purpose of this observational study is to test a shoe mounted gait monitoring device that was refined with the input of older adults and assess the efficacy of the refinements through a series of tests that involve walking with and without the device.",[283],"Seniors",{"date":64,"type":37},{"date":131,"type":21},{"date":287,"type":21},"2027-09",{"name":43,"class":44},{"id":290,"slug":4,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":308,"locationsCount":45},"100585844","NCT06907654","Couples' Affect in Relationships Study","Cares","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Be either married, living together, OR in a dating relationship for at least 12 months\n* Proficiency in English\n* US citizen or permanent resident\n* If non-monogamous, must be able to enroll in the study with a primary partner with whom they spend the majority of their time.\n* Use of a smartphone (primary participant only)\n* Phone able to receive SMS text messages\n* Depression symptoms (≥ 5 on PHQ-9; primary participant only)\n\nExclusion Criteria:\n\n* Severe physical or sexual relationship aggression during the past 6 months (any item endorsement on 5-item severe IPV screener)\n* Endorsement of active suicidality\n* History of psychosis or mania\n* Prior use of the Healthy Minds Program app\n* Prior significant experience with meditation\n* Severe hearing impairment that would interfere with the use of an audio-based intervention (primary participant only)",{"count":296,"type":21},2000,[24],"The goal of this clinical trial is to find out whether learning about well-being impacts the thoughts and feelings of romantic couples. The main question it aims to answer is:\n\n* Does gaining knowledge about well-being positively impact individuals and their romantic relationships?\n\nParticipants will complete online surveys about their thoughts and feelings.",[300],"Depression Disorders",[302,303],"romantic relationship","long-term relationship",{"date":64,"type":37},{"date":66,"type":21},{"date":307,"type":21},"2028-12",{"name":43,"class":44},{"id":310,"slug":4,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":330,"locationsCount":45},"100573480","NCT06746831","Methamphetamine Isomer Pharmacology in Humans","The Low-Down on Methamphetamine Isomers: Prevalence and Pharmacology in Humans","Inclusion Criteria:\n\n* Good mental health as determined by self-reported responses to the Psychopathology Screener\n* Absence of any major cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal, or hepatic disease as determined by self-reported responses to the Medical History Screener\n* English-speaking (able to provide consent and complete questionnaires)\n* Written Informed Consent\n\nExclusion Criteria:\n\n* Any serious prior adverse response to sympathomimetic agents or amphetamine analogs\n* History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener\n* Pregnancy or lactation (pregnancy test, if needed)\n* Use of medications that may impact cognition or metabolism (e.g., mood stabilizers, sedatives)\n* Dependent on prohibited concomitant therapy that cannot be withheld for 48 hours prior to and during study visits.","64 Years",{"count":317,"type":21},17,[124],"This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.",[321],"Methamphetamine",[323,324,325],"pharmacology","meth","isomers",{"date":64,"type":37},{"date":66,"type":21},{"date":329,"type":21},"2028-03",{"name":43,"class":44},{"id":332,"slug":4,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":346,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":45},"100531932","NCT06206226","The Oh Happy Day Class - Digital Connections (OHDC-DC): A Pilot Study","The Oh Happy Day Class - Digital Connections (OHDC-DC): an Exploratory Pilot Study","OHDC-DC","Inclusion Criteria:\n\n* African-American\n* Age 18 and older\n* Experiencing depression (as evidenced by a score of 5 or higher on the PHQ-9)\n* Own a mobile phone\n\nExclusion Criteria:\n\n* Individuals who are currently receiving psychotherapy\n* Individuals who are presently experiencing suicidal ideation\n* Individuals who started psychotropic medication less than three months prior to the start of the OHDC will be excluded from the study\n* Participants scoring 25 or higher on the PHQ-9 will be screened out",{"count":339,"type":21},8,[24],"The goal of this clinical trial is to see if a mobile phone app can deliver depression treatment to African Americans who are depressed. The main question it aims to answer is if this treatment is effective in reducing symptoms of depression.\n\nParticipants will attend six 90-minute weekly classes via an app on their phone, and will be asked to complete surveys every week. Participants can expect to be in the study for four months.",[343,344,345],"Depression","Depressive Disorder","Depressive Symptoms",[347],"African American",{"date":64,"type":37},{"date":66,"type":21},{"date":351,"type":21},"2027-02",{"name":43,"class":44},{"id":354,"slug":4,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":16,"minAge":359,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":369,"leadSponsor":371,"locationsCount":4},"100424396","NCT04806347","Alpha\u002FBeta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults","TCRαβ+ and CD19+ Depleted Hematopoietic Stem Cell Transplant From Closely Matched Unrelated Donors or Haploidentical Related Donors for Hematologic Diseases in Children and Young Adults","Inclusion Criteria:\n\n* No Human leukocyte antigen (HLA) identical sibling available AND\n* NO HLA matched unrelated donor available OR urgent need of HSCT precludes time necessary to search for suitable HLA matched unrelated donor AND\n* Haploidentical donor OR closely matched unrelated donor available and willing to undergo mobilization and apheresis\n* If subject has genetically confirmed inherited bone marrow failure, related donor must be evaluated for this disorder and testing must be negative.\n* If subject has sickle cell disease, donor must be unaffected or have only sickle cell trait\n* Patient must be diagnosed with one of the following diseases or disorders:\n\n  * Hemoglobinopathies\n\n    * Sickle Cell Disease for patients ≤ 21 years of age for whom hydroxyurea has been trialed for at least six months, and failed\n    * Thalassemia Major for patients ≤ 21 years of age\n  * Acquired Bone Marrow Failure Syndromes\n\n    * Paroxysmal Nocturnal Hemoglobinuria with bone marrow failure\n    * Myelodysplastic Syndromes (lower risk)\n    * Severe acquired aplastic anemia\n  * Inherited Bone Marrow Failure Syndromes\n\n    * Fanconi Anemia\n    * Diamond Blackfan Anemia\n    * Dyskeratosis Congenita and related telomere disorders\n    * Congenital Thrombocytopenia Syndromes\n    * Severe Congenital Neutropenia\n    * Shwachman-Diamond Syndrome\n  * Inborn Errors of Immunity (IEI) or Primary Immune Regulatory Disorders (PIRD)\n\n    * Wiskott-Aldrich syndrome (WAS)\n    * Chronic granulomatous disease (CGD)\n    * Severe combined immunodeficiency (SCID)\n    * Primary hemophagocytic lymphohistiocytosis (HLH)\n* Age ≤ 25 years (except patients with hemoglobinopathies)\n* Life Expectancy ≥ 3 months\n* Karnofsky (patients \\> 16 years)\u002FLansky (patients ≤ 16 years) index ≥ 60\n* Organ Function Requirements\n\n  * Renal Function\n\n    * Creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) greater than or equal to 60 ml\u002Fmin\u002F1.73m\\^2\n  * Liver Function\n\n    * Total bilirubin \\\u003C 3 mg\u002FdL\n    * Alanine aminotransferase (ALT)\u002F Serum glutamic-pyruvic transaminase; synonymous with ALT (SCPT) ≤ 3 x Upper Limit of Normal (ULN) for age\n  * Cardiac Function\n\n    * Ejection fraction of \\> 40% by Multiple gated acquisition scan (MUGA) or echocardiogram\n  * Pulmonary Function\n\n    * No evidence of dyspnea at rest\n    * No supplemental oxygen requirement\n    * If measured, carbon monoxide diffusion capacity (DLCO) \\> 50%\n* Willing to use effective birth control method if patient is of reproductive potential\n* Informed consent obtained (patient or legal representative)\n\nExclusion Criteria:\n\n* Pregnant\n* HIV infection\n* Uncontrolled, serious active infection at screening\n* Significant serious intercurrent illnesses\n* Enrollment in any other treatment study that would interfere with the endpoints of this study according to judgement of Principal Investigator (or PI designee).","3 Months","25 Years",{"count":362,"type":21},12,[124],"This study is being done to see if the investigators can take peripheral blood stem cells from either an adult family member or a closely matched unrelated donor, and run them through a special lab instrument to remove alpha\u002Fbeta T cells and B cells and then give them to the patient to treat disease. This is an experimental way of doing a hematopoietic stem cell transplant (HSCT). The investigators want to see if the new stem cells will grow without bad graft vs. host disease (GVHD). This treatment approach is experimental in the United States.",[366],"Blood Disease",{"date":64,"type":37},{"date":66,"type":21},{"date":370,"type":21},"2030-05",{"name":43,"class":44},{"id":373,"slug":4,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":392,"leadSponsor":394,"locationsCount":45},"100645252","NCT07680114","Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls","A Pilot Feasibility Study of Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls","ONSETS","Inclusion Criteria (all participants):\n\n* U.S. citizen or holding permanent resident status\n* English-speaking\n\nInclusion Criteria (Participants with SSD):\n\n* DSM-5 schizophrenia spectrum disorder (SSD) diagnosis, defined as schizophrenia, schizoaffective disorder, or schizophreniform disorder (confirmed by clinical interview and\u002For chart review)\n* Chronic illness, defined as diagnosis of SSD for at least 1 year\n* Clinically stable outpatient (no psychiatric hospitalization in past 6 months; no change in antipsychotic medication in the past 6 weeks)\n\nInclusion Criteria (Healthy Controls):\n\n* Medically healthy (based on self-report and study team review)\n* Matched to SSD participants on age (±5 years) and sex\n\nExclusion Criteria (all participants):\n\n* Current or past history of clinically significant neurological disorder or acquired neurological disease (e.g., stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified on the structural MRI)\n* Active suicidal ideation, plan, or intent (assessed via PHQ-9 item 9 and follow-up Columbia-Suicide Severity Rating Scale (C-SSRS) Screener; see Safety Response Procedure)\n* Inability to provide informed consent, including inadequate decisional capacity in the judgment of the study team and\u002For study psychiatrist\n* History of head trauma resulting in prolonged loss of consciousness; or a history of \\>3 grade I concussions\n* Current poorly controlled headaches, including intractable or frequent migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Possible pregnancy or plan to become pregnant in the next 6 months (self reported)\n* Any metal in the head\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)\n* Dental implants\n* Permanent retainers\n* Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions\n* Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions\n* Current use of medications known to substantially lower seizure threshold, specifically chlorpromazine, clozapine, bupropion, clomipramine, or maprotiline; or other medications at doses known to substantially lower seizure threshold in the judgment of the PI or Study Psychiatrist\n* Current use of medications known to directly and substantially enhance sleep spindle activity, including benzodiazepines; non-benzodiazepine \"Z-drug\" hypnotics (zolpidem, eszopiclone, zaleplon); barbiturates; and gabapentin or pregabalin, within 2 weeks of the overnight study visits. Other sedating medications used as sleep aids (e.g., trazodone, hydroxyzine, mirtazapine) are permitted provided the regimen is stable across the two overnight visits; dose and timing will be recorded as covariates\n* Current moderate-to-severe alcohol or other substance use disorder (DSM-5) other than nicotine or caffeine\n* Active scalp lesions, broken skin, or skin conditions at planned electrode sites that would preclude safe electrode application\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for up to two hours\n* Regular night-shift work (second or third shift)\n* Sleep apnea or other sleep disorder (self-reported)\n\nExclusion Criteria (Healthy Controls):\n\n* Self-reported history of inpatient psychiatric hospitalization\n* Self-reported current or past diagnosis of schizophrenia or any other psychotic disorder\n* Self-reported first-degree relative with schizophrenia or any other psychotic disorder\n* Self-reported current or past diagnosis of bipolar disorder or major depressive disorder with psychotic features, or current treatment for any psychiatric disorder other than depression or anxiety (handled via the medication rule below)\n* Current use of any psychotropic medication, with the exception of a single SSRI or SNRI taken at a stable dose for at least 6 weeks for depression or anxiety. Current use of antipsychotics, tricyclic antidepressants, mirtazapine, trazodone, lithium or other mood stabilizers, benzodiazepines, non-benzodiazepine hypnotics, other anxiolytics, or stimulants will result in exclusion.","50 Years",{"count":161,"type":21},[24],"This study to find out whether a type of non-invasive electrical brain stimulation called transcranial electrical stimulation with temporal interference (TES-TI) can temporarily change brain activity during sleep-especially sleep spindles (brain rhythms in the \\~8-16 Hz range). The investigators are focusing on the thalamus, a deep brain region that helps coordinate brain activity during non-REM sleep. Sleep spindles are often reduced in schizophrenia, so this study is to see whether TES-TI can change spindle activity in individuals with schizophrenia spectrum disorders (SSD) and in healthy adults. To study this, a structural MRI scan will be used to customize where the stimulation electrodes are placed, and then TES-TI will be applied during one of two overnight sleep lab visits while brain activity is recorded with high-density EEG and standard sleep sensors. The other overnight is a baseline\u002Fcontrol night during which only sham stimulation is delivered. The goal is to determine whether TES-TI during sleep can increase spindle-frequency activity in this population.",[384],"Schizophrenia",[386,387,388],"schizophrenia spectrum disorders","sleep spindles","transcranial electrical stimulation with temporal interference","2026-06-25",{"date":110,"type":37},{"date":39,"type":21},{"date":393,"type":21},"2027-12",{"name":43,"class":44},{"id":396,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":25,"conditions":399,"keywords":400,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":406,"locationsCount":45},"100644933",{"count":20,"type":21},[24],[27],[29,30,31,32],"2026-06-24",{"date":62,"type":37},{"date":404,"type":21},"2026-06",{"date":91,"type":21},{"name":43,"class":44},{"id":408,"slug":4,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":422,"locationsCount":4},"100645223","NCT07678242","The Lucida Project","Inclusion Criteria - all participants:\n\n* Age 18 to 84\n* Elevated depressive symptoms: PHQ-9 ≥ 10; Healthy controls: PHQ-9 \\\u003C5\n\nInclusion Criteria - randomized participants:\n\n* Proficient in English to try to unsure understanding of study requirement, consent forms and questionnaires that can often us medical terms not routinely used in general conversation.\n* Able to provide informed consent\n* Have access to a smartphone that can download apps from Google Play or the Apple App Store\n* Ability to receive text messages\n* Indicate interest in participation after being informed of restrictions to payment\n\nExclusion Criteria:\n\n* Regular daily meditation practice for past 6 months or regular weekly meditation practice for past 12 months\n* Attended a meditation retreat or a yoga\u002Fbody practice retreat with a significant meditation component\n* Previous use of Healthy Minds Program app\n* Current suicidal intent and\u002For high self-injury risk (determined by PHQ-9 item 9 and BDI item 9)\n* Self-reported history of psychosis\n* Self-reported history of mania\n* Living or traveling outside the US during the whole study participation period (trips outside US after the interview phase is not an exclusion)\n* Hearing impairments\n* Prior participation\n* Self report pregnancy","84 Years",{"count":414,"type":21},1500,[24],"The purpose of this clinical trial is to learn about the impact of the Healthy Minds Program (HMP) on measurements of well-being. The main question it aims to answer is:\n\n* Does use of HMP reduce symptoms of depression?\n\nParticipants will complete a 4-week well-being program.",[418],"Depression Disorder",{"date":64,"type":37},{"date":39,"type":21},{"date":149,"type":21},{"name":43,"class":44},{"id":424,"slug":4,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":52,"sex":428,"minAge":17,"maxAge":120,"enrollmentInfo":429,"targetDuration":4,"studyType":280,"phases":4,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":439,"locationsCount":45},"100571600","NCT06722365","Characterization of Fetal Lung With Quantitative Ultrasound","Inclusion Criteria:\n\n* Pregnant females ages 18 to 45 years old with singleton pregnancy, live fetus, gestational age between 32.1 and 36.7 weeks, not in labor, scheduled for routine ultrasound growth evaluation.\n* Gestational age determined by the date of the last menses, and confirmed by measurement of the crown-rump-length on transabdominal ultrasound.\n\nExclusion Criteria:\n\n* Subjects unable to consent\n* Active Labor\n* Fetal malformations of the lungs\n* Prescription of corticosteroids prior to ultrasound evaluation\n* Pre-gestation or gestational diabetes mellitus\n* Low English proficiency, needing an interpreter","FEMALE",{"count":430,"type":21},16,"The purpose of the study is to show if it's possible to use a special kind of ultrasound called backscatter quantitative ultrasound (bQUS) to check on a baby's lungs when the mother is 36 weeks pregnant. 16 participants will be on study for a single 30 minute ultrasound between 32 and 36 weeks of pregnancy.",[433,434],"Respiratory Complication","Fetal Lung Imaging",{"date":389,"type":37},{"date":437,"type":37},"2024-12-17",{"date":91,"type":21},{"name":43,"class":44},{"id":441,"slug":4,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":22,"phases":448,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":458,"locationsCount":45},"100406500","NCT04573231","Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer","Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET\u002FCT","Inclusion Criteria:\n\n* Patients diagnosed with metastatic HER2-negative breast cancer AR expression of ≥ 10%\n\nExclusion Criteria:\n\n* Other (non-breast) known active malignancy. Participants with previously treated cancers which are in remission or have no evidence of disease are eligible.\n* Unable to lie flat during or tolerate PET\u002FCT\n* Participants with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or completing the study\n* Women of childbearing potential must not be pregnant or breast feeding (pregnancy test negative within 7 days prior to PET\u002FCT",{"count":447,"type":21},13,[103],"The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will correlate with resistance to anti-androgen therapies, as has been documented in prostate cancer, and this can be used to select patients most likely to benefit from these therapies in future clinical trials. 15 people with HER2-negative, AR-positive metastatic breast cancer will be enrolled and be on study for about 3 days.",[451,452,453],"Breast Cancer","HER2-negative Breast Cancer","Metastatic Breast Cancer",{"date":389,"type":37},{"date":456,"type":37},"2021-05-24",{"date":66,"type":21},{"name":43,"class":44},{"id":460,"slug":4,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":45},"100637042","NCT07573540","Optimizing Smart Technology for Addiction Recovery","Optimizing Algorithmic Feedback About Lapse Risk for Trust, Engagement, and Clinical Outcomes for Alcohol Use Disorder","STAR","Inclusion Criteria:\n\n* meet criteria for alcohol use disorder with at least moderate severity (\\>= 4 DSM-5 criteria)\n* in initial remission with most recent use of alcohol between 1 week and 3 months in the past\n* able to read English\n* have a smartphone and cellular plan that supports STAR use (Apple iOS or Android)\n\nExclusion Criteria:\n\n* medical or psychiatric co-morbidities that preclude use of a smartphone",{"count":467,"type":21},416,[24],"The goal of this study is to develop a machine-learning guided recovery messaging system. The main question it aims to answer is can messages be used to:\n\n* help people to improve their health\n* make changes in people's lives to address alcohol and substance use\n\nParticipants will:\n\n* complete surveys\n* use a recovery-support digital therapeutic system",[471,472],"Alcohol Use Disorder","Alcohol Use Disorder (AUD)","2026-06-22",{"date":389,"type":37},{"date":476,"type":37},"2025-09-24",{"date":478,"type":21},"2029-07-31",{"name":43,"class":44},{"id":481,"slug":4,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":45},"100374067","NCT04150640","Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma","Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma","Inclusion Criteria:\n\n* Written informed consent and HIPAA authorization for release of personal health information.\n\nNOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.\n* Histological or cytological confirmed locally advanced or metastatic EGA. Known HER2 status prior to treatment initiation required. Known PDL1 CPS status prior to treatment initiation.\n* Measurable disease according to RECIST v1.1.\n* No prior lines of systemic therapy for advanced disease.\n* Participants who had received neoadjuvant or adjuvant therapy or definitive chemoradiation will be allowed to participate if recurrence occurred 6 months or longer from the completion of all prior treatments.\n* Demonstrate adequate organ function as defined below; all screening labs to be obtained within 14 days prior to registration\n\n  * Absolute Neutrophil Count (ANC) ≥1,500 \u002Fμl without the use of hematopoietic growth factors\n  * Hemoglobin (Hgb) ≥8 g\u002FdL (blood transfusions are permitted for participants with hemoglobin levels below 8 g\u002FdL)\n  * Platelets ≥100,000 \u002Fμl\n  * Serum creatinine ≤1.5 X upper limit of normal (ULN) OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl). CrCl calculation using the Cockcroft-Gault formula. ≥50 mL\u002Fmin for participants with creatinine levels \\> 1.5 X institutional ULN\n  * Bilirubin within normal range for the institution (biliary drainage is allowed for biliary obstruction); abnormal bilirubin (≤1·5 × upper limit of normal (ULN)) is allowed for patients with Gilbert's disease\n  * Aspartate aminotransferase (AST) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases\n  * Alanine aminotransferase (ALT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases\n  * International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n  * Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n* Women of childbearing potential should have a negative urine or serum pregnancy test within 14 days of study registration. NOTE: Women are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months\n* Women of childbearing potential and males must be willing to abstain from heterosexual activity or to use a form of effective method of contraception from the time of informed consent until 30 days after treatment discontinuation.\n* As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.\n\nExclusion Criteria:\n\n* Known hypersensitivity to 5-FU, oxaliplatin or other platinum agents, or any of the components of nal-IRI and other liposomal products.\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency (testing not required prior to enrollment).\n* Other active malignancy requiring treatment within the last 2 years. Exceptions include subjects with non-melanoma skin cancer, non-invasive\u002Fin situ cancer or low-risk prostate cancer requiring hormonal therapy only.\n* Current therapy with other investigational agents or participation in another clinical study (supportive care and nontherapeutic trial participation allowed if not receiving an investigational drug). Participants may participate in prescreening for other therapeutic trials (prescreening of biologic sample for specific mutations, receptors, etc.)\n* Major surgery within 28 days or minor surgery within 14 days of the start of the study treatment, except for tumor biopsy or placement of central infusion device (port placement).\n* Radiotherapy less than 7 days prior to the start of the study treatment\n* Participants who receive nivolumab or pembrolizumab in addition to chemotherapy should not have any contraindications to immune checkpoint inhibitors and should not have received immunotherapy agents for the treatment of EGA prior to study enrollment.\n\n  * Participants must not have active autoimmune disease that has required systemic treatment in the past 2 years. Participants are permitted to receive immunotherapy l if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event).\n  * Participants must not have a condition requiring systemic treatment with either corticosteroids (\\>10 mg\u002Fday prednisone equivalents) or other immunosuppressive medications within 14 days of study immunotherapy administration. Inhaled or topical steroids and adrenal replacement doses (≤10 mg\u002Fday prednisone equivalent) are permitted. Participants with prior immune mediated adverse events related to immunotherapy that resulted in permanent treatment discontinuation with these agents.\n* Psychological, familial, or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.\n* Active infection requiring systemic therapy.\n* Pregnant or breastfeeding.\n* Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability.\n* Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before inclusion.\n* NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure.\n* Known history of Human Immunodeficiency Virus (HIV).",{"count":487,"type":21},52,[103],"This is an open label, phase II, multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin, nal-IRI, and immunotherapy (plus trastuzumab for HER2-positive tumors) as first-line therapy for participants with advanced Esophageal and Gastric Adenocarcinoma (EGA). The investigators hypothesize that this drug combination will be better tolerated than current first-line chemotherapy combinations for this disease.",[491,492],"Esophageal Adenocarcinoma","Gastric Adenocarcinoma","2026-06-18",{"date":495,"type":37},"2026-06-23",{"date":497,"type":37},"2020-07-13",{"date":499,"type":21},"2028-05",{"name":43,"class":44},{"id":502,"slug":4,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":22,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":45},"100561845","NCT06595459","The Options 2 Study","A Randomized Comparative Effectiveness Trial of Nicotine Pouches for Cigarette Substitution: A Question of Public Health","Inclusion Criteria:\n\n* ≥ 21 years old (i.e., able to legally purchase tobacco products)\n* able to read and communicate in English\n* no plans to quit smoking in the next 30 days\n* willing to stop using nicotine replacement or varenicline\n* willing to stop using bupropion (i.e., Wellbutrin, Zyban) if they are currently using it only for smoking cessation\n* smoking ≥ 5 cigarettes per day for the past 6 months\n* exhaled carbon monoxide ≥ 6 ppm\n* no nicotine pouch or smokeless tobacco (including snus) use within the last 6 months\n\nExclusion Criteria:\n\n* currently in treatment for psychosis or bipolar disorder\n* currently taking bupropion for non-smoking cessation reasons (e.g., Wellbutrin for depression)\n* currently pregnant or breastfeeding",{"count":508,"type":21},300,[57],"The goal of this clinical trial is to investigate how well nicotine pouches and nicotine mini lozenges serve as substitutes for cigarettes when people try to switch from smoking to using these alternate nicotine products.\n\nParticipants will:\n\n* Use nicotine pouches, nicotine mini lozenges, or no study product for a week and then try not to smoke for 3 weeks.\n* Have 6 in-person research visits and 1 follow-up call\n* Complete questionnaires at each study contact and use a smartphone app to record smoking and study product use",[512,60],"Smoker","2026-06-17",{"date":473,"type":37},{"date":516,"type":37},"2025-05-21",{"date":518,"type":21},"2029-07-30",{"name":43,"class":44},{"id":521,"slug":4,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":526,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":529,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":45},"100546267","NCT06392711","Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","UW23129: A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","Inclusion Criteria:\n\n* Xerostomia, defined as an unstimulated salivary flow \\\u003C1.2 mL in 5 minutes documented at any time following xerostomia diagnosis and prior to enrollment\n* Xerostomia not resulting from radiotherapy (medical xerostomia)\n* ≥ 18 years of age, ≤ 90 years of age\n* Karnofsky performance status ≥ 70, patient eligible for bone marrow aspirate with wakeful anesthesia\n* Willing and able to give informed consent\n* Radiographically confirmed bilateral submandibular glands\n* If female of childbearing potential, negative pregnancy test\n* Males and females of childbearing potential willing to use acceptable contraception\n* Laboratory Values (within 28 calendar days of enrollment):\n\n  * Hgb ≥ 9 g\u002FdL (5.58 mmol\u002FL)\n  * Platelets ≥ 100,000\u002FµL\n  * ANC ≥ 1000\u002FµL\n  * Lymphocytes ≥ 800\u002FµL\n  * PT\u002FINR and PTT within normal limits based on age\u002Fsex\n\nExclusion Criteria:\n\n* Patients with one submandibular gland\n* Sialolithiasis\n* Poorly-controlled diabetes mellitus (HbA1c ≥ 7%)\n* Patients who initiated any diuretic therapy before developing dry mouth symptoms and are still on diuretic therapy and the referring provider believes the dryness symptoms are driven by diuretic use\n* Untreated oral candidiasis based on physical exam at enrollment\n* Malignancy within the last 2 years (except adequately treated stage I lung cancer, low risk prostate cancer that has been treated or is undergoing active surveillance, adequately treated non-melanoma skin cancer, adequately treated DCIS, or adequately treated stage I cervical cancer)\n* For patients on immunosuppressive therapy, must be on stable dose of immunosuppressive therapy for at least 2 months, allowing for dose adjustments for blood levels of drugs\n* Transfusion dependency\n* Life expectancy ≤ 6 months as determined by the investigator\n* Use of investigational drugs, biologics, or devices within 30 calendar days prior to enrollment\n* Pregnant or lactating women or those who plan to become pregnant during the study\n* Not suitable for study participation due to other reasons at discretion of investigators.\n* Enrollment in another clinical study possibly interfering with the endpoints of this study","90 Years",{"count":528,"type":21},36,[124],"The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells (MSCs) into salivary glands. The main question it aims to answer is whether injection of MSCs into salivary glands results in any improvement in dry mouth.\n\nParticipants will:\n\n* have bone marrow collected using a needle\n* undergo a salivary gland ultrasound\n* complete questionnaires\n* receive an injection of the bone marrow cells into a salivary gland",[532,533,534],"Xerostomia","Graft-versus-host-disease","Sjogren's Disease",{"date":473,"type":37},{"date":537,"type":37},"2024-10-04",{"date":539,"type":21},"2028-11",{"name":43,"class":44},""]